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Resolvins are a family of n-3 lipid mediators initially
identified in resolving inflammatory exudates that
temper inflammatory responses to promote cataba-
sis. Here, temporal metabololipidomics with self-
limited resolving exudates revealed that resolvin
(Rv) D3 has a distinct time frame from other lipid
mediators, appearing late in the resolution phase.
Using synthetic materials prepared by stereocon-
trolled total organic synthesis and metabololipido-
mics, we established complete stereochemistry
of RvD3 and its aspirin-triggered 17R-epimer (AT-
RvD3). Both synthetic resolvins potently regulated
neutrophils and mediators, reducing murine perito-
nitis and dermal inflammation. RvD3 and AT-RvD3
displayed leukocyte-directed actions, e.g., blocking
human neutrophil transmigration and enhancing
macrophage phagocytosis and efferocytosis. These
results position RvD3 uniquely within the inflamma-
tion-resolution time frame to vantage and contribute
to the beneficial actions of aspirin and essential n-3
fatty acids.
INTRODUCTION
In response to stress and/or invasion, acute inflammation is
host-protective (Medzhitov, 2010) and, when uncontrolled,
unresolved inflammation is linked to many widely occurring
diseases (Dinarello, 2010; Majno et al., 1982; Nathan and
Ding, 2010; Tauber and Chernyak, 1991). The ideal outcome
for an acute inflammatory response is complete resolution. In
this context, in self-limited inflammatory exudates, we identified
potent local mediators within the resolution phase that possess
potent anti-inflammatory and proresolving actions, coined
specialized proresolving mediators, that include the resolvins,
protectins, and maresins (for reviews, see Serhan, 2007 and
Serhan and Petasis, 2011). Thus, within the initiation phase,
chemical mediators, such as prostaglandins, leukotrienes,
cytokines, and chemokines, dictate the leukocyte influx traffic
(Dinarello, 2010; Samuelsson, 2012) that is actively counter-
regulated by proresolving mediators, which orchestrate the188 Chemistry & Biology 20, 188–201, February 21, 2013 ª2013 Elseresolution phase, catabasis, and the return to homeostasis
(Serhan, 2007).
The resolvins are biosynthesized from essential omega-3 fatty
acids (Serhan, 2007; Serhan et al., 2002; Serhan and Petasis,
2011). The E-series resolvins, i.e., resolvin E1, resolvin E2, and
resolvin E3 (Isobe et al., 2012), are produced from eicosapentae-
noic acid (EPA) (reviewed in Serhan, 2007 and Serhan and
Petasis, 2011). D-series resolvins, including resolvin (Rv)D1
(Sun et al., 2007), RvD2 (Spite et al., 2009), RvD5 (Chiang
et al., 2012), and their aspirin-triggered versions are biosyn-
thesized from DHA (Serhan et al., 2002). Each resolvin
possesses potent proresolving actions that include limiting
neutrophil tissue infiltration, counterregulation of chemokines
and cytokines, reduction in pain, and stimulation of macro-
phage-mediated actions (i.e., efferocytosis and bacterial and
debris clearance). Given their unique mechanism of proresolving
actions, resolvins demonstrate potent actions in animal disease
models (reviewed in Serhan and Petasis, 2011). Like many
other autacoids, the actions of resolvins are stereochemically
selective, reflecting their routes of biosynthesis. The classic
eicosanoids, for example, each carry well-established stereose-
lectivity in their actions (Samuelsson, 2012; Shimizu, 2009).
Hence, establishing the complete stereochemical assignment
for each of the separate resolvin structures is of considerable
interest.
The original identification of the D-series resolvins reported
the structural elucidation of several distinct bioactive structures,
denoted resolvin D1 through resolvin D6, in resolving murine
exudates, their biosynthesis by isolated human leukocytes,
and potent actions in vivo in murine as well as human acute
inflammation (Serhan et al., 2002). From the basic structures of
the D-series resolvins, it was deemed important to establish
each of their complete stereochemical assignments to permit
further mass spectral quantitative methods for in vivo studies
as well as confirmation and extension of their roles in inflamma-
tion and active resolution. Along these lines, we determined the
complete stereochemical assignments of RvD1 as 7S,8R,17S-
trihydroxydocosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid and
its aspirin-triggered AT-(17R epimer)-RvD1 as 7S,8R,17R-
trihydroxydocosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid, em-
ploying a stereocontrolled total organic synthesis approach
that permitted confirmation of RvD1 potent anti-inflammatory
and proresolving actions (Serhan and Petasis, 2011; Sun et al.,
2007) as well as documented RvD1 production by human
neutrophils, blood, trout hematopoietic organs, and in brainvier Ltd All rights reserved
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Figure 1. Endogenous Biosynthesis of RvD3 and Its Relation to
Other Lipid Mediators in Inflammation Resolution
Mice were injected i.p. with zymosan (1 mg/mouse) and lavages collected at
the indicated intervals.
(A) Total cell counts in the peritoneal exudates were determined by light
microscopy and the number of mononuclear cells and PMN determined
by flow cytometry. Lipid mediators in exudates were assessed using LC-MS-
MS metabololipidomics following solid phase extraction (see Experimental
Procedures).
(B and C) Exudate levels for (B) prostaglandins and leukotrienes and (C)
D-series resolvins. Results are mean ± SEM n = 3–4 mice per time point.
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and extended to controlling pain (Ji et al., 2011; Lima-Garcia
et al., 2011; Xu et al., 2010), reducing airway inflammation
(Rogerio et al., 2012) murine colitis (Bento et al., 2011)
and stimulating resolution mechanisms in vivo in mice and
with human macrophages in vitro (Recchiuti et al., 2011) as
well as RvD1 identification in human blood (Mas et al., 2012;
Psychogios et al., 2011). For resolvin D2, establishing itsChemistry & Biology 20, 188complete stereochemistry as 7S,16R,17S-trihydroxydocosa-
4Z,8E,10Z,12E,14E,19Z-hexaenoic acid permitted the identifi-
cation of resolvin’s ability to enhance the innate immune
response without rendering immune suppression of the host
(Spite et al., 2009). This also enabled the elucidation of the potent
protective and proresolving actions of RvD2 in colitis (Bento
et al., 2011), in reducing pain (Ji et al., 2011), and its presence
in both human tissue (Mas et al., 2012) and salmon (Raatz
et al., 2011).
The basic structure 4S,11,17S-trihydroxydocosa-5Z,7,9,13,
15E,19Z-hexaenoic acid, identified in murine exudates and
with human leukocytes, was denoted resolvin D3 (RvD3) (Serhan
et al., 2002). By definition, resolvin D3 actions include potent
reduction of neutrophil infiltration in vivo in both murine perito-
nitis and dorsal skin pouches. RvD3 also reduced human
neutrophil transendothelial migration (Serhan et al., 2002), each
cardinal actions of a proresolving mediator. Of interest, RvD3
from endogenous sources of DHA is elevated in colitis in fat-1
transgenic mice that overexpress the enzyme that increases
tissue levels of n-3 essential fatty acids without feeding DHA or
EPA (Hudert et al., 2006). Also, RvD3 produced from endoge-
nous DHA is elevated in ischemic injury of the kidney (Duffield
et al., 2006). Given these properties, we have focused on
establishing RvD30s complete stereochemistry and temporal
positioning within inflammation resolution. Here, we report
the stereochemical assignments for both RvD3 and aspirin-
triggered (AT)-RvD3 and their potent anti-inflammatory and
proresolving actions using synthetic materials, establishing the
potent actions of these members of the D-series resolvins.
RESULTS
RvD3 Is Uniquely Positioned within the Resolution
Frame of Inflammation
Self-limited inflammation results in a rapid increase in infiltration
of neutrophils and their eventual loss from the tissue (Figure 1A).
This is accompanied by a concomitant nonphlogistic increase
in mononuclear cells. In this context, the resolution interval
(Bannenberg et al., 2005) was 11 hr. Each cell population
was identified using flow cytometry and light microscopy (see
inset for 12 and 24 hr). This system is an ideal example of the
temporal relationship from initiation to resolution (Bannenberg
et al., 2005). In this context, prostaglandins are rapidly produced
(Figure 1B) and, concomitant with neutrophil infiltration into the
tissue, leukotriene B4 and prostaglandin E2 (PGE2) levels reach
maximum within 4 hr. Leukotriene B4 (LTB4) levels rapidly drop
and return to essentially baseline within 12 hr, whereas the levels
of both PGE2 and prostaglandin D2 (PGD2) persist into the
resolution phase, where they were shown earlier to stimulate
the production of proresolving mediators by stimulating the
transcriptional regulation of a key enzyme in this process, human
15-lipoxygenase type 1 (Levy et al., 2001).
Using this setting, which amply qualifies the initiation and reso-
lution phase, we next determined the profile of D-series resolvins
within the DHA metabolome in order to temporally stage each
(Figure 1C). As anticipated, endogenous production of resolvins
D1, D2, and D5 lagged behind appearance of the leukotrienes
and was coincident with the resolution phase as determined
from a maximal PMN time point (Tmax) to the 50% reduction in–201, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 189
Figure 2. Synthetic RvD3/AT-RvD3 Stereoisomers
These isomers were prepared in enantiomerically pure form via stereo-
controlled total synthesis and were fully characterized by NMR spectros-
copy.
(A) Structures of the isomers of RvD3/AT-RvD3 and color-coded illustration
depicting the origin of R or S stereochemistry of each chiral alcohol group from
stereochemically pure precursors (J.W.W., C.N.S., and N.A.P., unpublished
data).
(B) Assignment of the Z or E stereochemistry for each C = C bond using two-
dimensional NMR spectroscopy. The shown 1H-1H gCOSY spectrum of
a solution of RvD3 in CD3OD [9.6 3 10
3M] was acquired using a Varian
VNMRS 600 MHz NMR spectrometer at 25C on a 5 mm Triple Resonance
PFG 1H and referenced to the CD3OD and an internal standard. This spectrum
depicts all of the connectivities between adjacent alkenyl hydrogens (H5-H10,
H13-H16, H19-H20). The colors denote a bitmap plottingmethod using a rainbow
palette that gives depth to the positive and negative contours. The complete
identification of each H-atom using this in combination with its corresponding
constants (J values) permitted the unambiguous E/Z assignment of all alkenyl
hydrogens (see Results).
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the levels of resolvin D3 increased at 24 hr after initiation and
persisted to 72 hr, well into the resolution timeframe of the local
inflammatory response. Thus, endogenous production of D-
series resolvins gave a distinct separation between resolvins
D1 and D2 accumulation early in the resolution phase and
the persistence of resolvin D3, which gives a unique position
within the resolution phase. Hence, we focused our attention
on resolvin D3.
Synthetic RvD3 and AT-RvD3
During the initial isolation and structural characterization of RvD3
and AT-RvD3 (Serhan et al., 2002), the E/Z stereochemistry of
all C = C bonds and the R/S chirality of the hydroxyl groups at
C4 and C11 could not be determined, since these structures
were deduced and proposed using results from liquid chroma-
tography-tandem mass spectrometry (LC-MS-MS) and gas
chromatography-mass spectrometry (GC-MS), which does not
permit direct determination of the stereochemical nature of
these molecules. In order to fully elucidate the stereochemical
assignments of these mediators, we devised a stereocontrolled
synthetic approach to obtain several potential stereoisomers
of these molecules (J.W.W., C.N.S., and N.A.P., unpublished
data). The complete structures of two synthetic RvD3 isomers,
the 17S-isomer 1 and the epimeric 17R-isomer 2, which were
obtained in stereochemically pure form, are shown in Figure 2A.
The complete structure and stereochemistry for both isomers
were unambiguously established through the stereocontrolled
synthetic approach and were confirmed via spectroscopic
analysis. The R/S chirality for each of the three OH groups
(Figure 2A) was ensured by starting with enantiomerically pure
starting materials with the same chirality and by employing
synthetic transformations that retain this chirality throughout
the synthesis. The Z/E geometry for each of the C = C bonds
was secured by employing highly stereocontrolled processes
that produce the desired geometry in each position. Further
structural confirmation and unambiguous assignment of the
Z/E geometry of each C = C bond for both isomer 1 and isomer
2were established via two-dimensional correlated spectroscopy
(COSY) nuclear magnetic resonance (NMR) spectroscopy (Fig-
ure 2B; see Experimental Procedures).
Matching of Endogenous RvD3 and AT-RvD3
with Synthetic Materials
Since both RvD3 and its aspirin-triggered epimer are produced
in murine inflammatory exudates (Duffield et al., 2006; Serhan
et al., 2002), it was important to establish the complete stereo-
chemistry as well as confirm its assigned structure and actions
with synthetic material prepared by stereocontrolled total
organic synthesis. To this end, authentic RvD3 and its aspirin-
triggered form (AT-RvD3) were obtained from endogenous
DHA in murine-resolving exudates treated with or without
aspirin and chromatographed using LC-MS-MS-based meta-
bololipidomics (Figures 3A and 3B) for direct comparison with
synthetic material (Figure 3C). Authentic RvD3 from both murine
exudates (Figures 3A and 3B) and human macrophages (Fig-
ure S1A available online) gave a sharp peak in liquid chromatog-
raphy, retention time (T R) = 7.4 min, clearly separating from
AT-RvD3, which produced a sharp peak at TR = 7.2 min.vier Ltd All rights reserved
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Figure 3. Endogenous RvD3 and AT-RvD3 from Resolving Inflammatory Exudates Match Synthetic Compound
(A) Endogenous RvD3 was obtained from mice injected with zymosan (1 mg/mouse) and exudates collected at 4 hr. These were subjected to lipid mediator
metabololipidomics. Selected ion chromatograms (m/z 375–147) depict murine-resolving exudate-derived RvD3.
(B) Endogenous AT-RvD3 obtained from mice administered aspirin (500 mg) and zymosan (1 mg).
(C) Synthetic isomers 1 and 2.
(D) Coinjection of resolving exudate endogenous RvD3 with synthetic isomer 1 (inset: characteristic UV-absorption spectrum) (see also Figures S2 and S3 and
Table S1).
(E) Coinjection of resolving exudate endogenous AT-RvD3 with synthetic isomer 2 (inset: characteristic UV-absorption spectrum).
(F–I) MS-MS spectrum for (F) endogenous RvD3 (TR = 7.4 min); (G) endogenous AT-RvD3 (TR = 7.2 min); (H) synthetic RvD3 (TR = 7.4 min); (I) synthetic AT-RvD3
(TR = 7.2min) (see also Figure S1). Representative MRM chromatograms and MS-MS spectra (n = 4).
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gave a sharp peak [TR = 7.4 min] and isomer 2 eluted at TR =
7.2 min (Figure 3C). Coinjection with material prepared by total
organic synthesis and authentic RvD3 demonstrated coelution
with isomer 1 at TR = 7.4 min (Figure 3D). Similarly, coinjection
of synthetic isomer 2 with authentic AT-RvD3 obtained from
aspirin-treated inflammation demonstrated coelution TR =
7.2 min (Figure 3E). Moreover, the two synthetic compounds
contained combined characteristic conjugated triene and
diene chromophores with triplet absorbance bands at lmax
MeOH
260, 271, and 281 nm for the triene and 236 nm band for the
diene component (Figures 3D and 3E, insets).Chemistry & Biology 20, 188Of interest, although the two RvD3 epimers displayed distinct
chromatographic behavior, they both demonstrated essentially
identical fragmentation patterns (Figures 3F–3I). Each diaste-
reomer gave m/z 375 = M-H, m/z 357 = M-H-H2O, m/z 339 =
M-H-2H2O, m/z 313 = M-H-CO2-H2O, m/z 295 = M-H-CO2-
2H2O, m/z 259 = 277-H2O, m/z 215 = 249-CO2, m/z 177 =
195-H2O, m/z 159 = 195-2H2O, m/z 147 = 165-H2O, and m/z
137 = 181-CO2.
To obtain further evidence for matching of RvD3, GC-MS was
performed as in the original identification and basic structural
elucidation (Serhan et al., 2002). RvD3 was treated with diazo-
methane and subsequently converted to its corresponding–201, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 191
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Resolvin D3 Is a Potent Immunoresolventtrimethylsilyl derivative (Figure S2A) and subjected to GC-MS.
The retention time in GC-MS for synthetic RvD3 corresponded
to a C value of 27.9 (Figure S2B), while the mass spectrum
(Figure S2C; Table S1) demonstrated fragmentation and ions
consistent with the proposed structure of RvD3 (Serhan et al.,
2002) and matched those of the derivatized synthetic materials
(see Experimental Procedures). AT-RvD3 demonstrated pro-
perties similar to RvD3 (Figure S3) with a retention time of
20.5 min (Figure S3B), corresponding to a C-value of 27.9
and displaying essentially an identical fragmentation pattern
to RvD3 in the GC-MS (Figure S3C). Therefore, the complete
stereochemistry of RvD3 was proved to be 4S, 11R, 17S-
trihydroxydocosa-5Z, 7E, 9E, 13Z, 15E, 19Z-hexaenoic acid
(isomer 1, Figures 3A and 3F), and that for AT-RvD3 was 4S,
11R, 17R-trihydroxydocosa-5Z, 7E, 9E, 13Z, 15E, 19Z-hexanoic
acid (isomer 2, Figures 3B and 3G).
RvD3 and AT-RvD3 Exert Potent Antineutrophil Actions
After matching the synthetic materials with endogenously
produced mediators and establishing the stereochemistry of
RvD3 and AT-RvD3, we required confirmation of their potent
anti-inflammatory actions. Systemic administration of RvD3
and its aspirin-triggered epimer in vivo immediately prior to
zymosan (1 mg) challenge at doses as low as 10 ng/mouse
significantly reduced the number of transmigrated neutrophils
into the peritoneal cavity (43%; Figure 4A). Assessment
of exudate cytokine and chemokine levels demonstrated a
significant downregulation of the proinflammatory cytokine
interleukin (IL)-6 (Figure 4B) and an increase in levels of the
proresolving cytokine IL-10 (Figure 4C).
The biosynthesis and action of specialized proresolving medi-
ators is regulated both temporally and spatially (Serhan and
Savill, 2005); therefore, we next assessed the actions of the
synthetic RvD3 diastereomers in murine dorsal air pouches.
Local administration of RvD3 significantly reduced neutrophil
transmigration in response to tumor necrosis factor alpha
(TNF-a)-initiated acute inflammation (65% reduction; Fig-
ure 4D). Assessment of inflammatory exudate cytokine and
chemokine levels demonstrated a significant reduction in
monocyte chemoattractant protein-1 (MCP-1) (70%), IL-6
(90%), and murine keratinocyte-derived cytokine/chemokine
(C-X-C motif) ligand 1 (KC) (50%) (Figures 4E–4G). Similarly,
AT-RvD3 potently reduced PMN recruitment into the pouch
(75%; Figure 4D), while also reducing exudate proinflammatory
cytokine and chemokine levels (Figures 4E–4G). Together,
these results demonstrate the potent local and systemic anti-
inflammatory actions of RvD3 and AT-RvD3, counterregulating
local proinflammatory mediator production and dampening
leukocyte recruitment.
RvD3 and AT-RVD3 Counterregulate Eicosanoids
Given that proresolving lipid mediators also regulate eicosanoid
biosynthesis (Spite et al., 2009), we next assessed the ability
of systemically delivered RvD3 as well as AT-RvD3 to regulate
local eicosanoid production in vivo. We performed lipid mediator
metabololipidomics using exudates obtained at 4 hr after
zymosan administration to identify potential mechanism(s)
underlying the actions of systemically administered RvD3 and
AT-RvD3. In these experiments, we targeted and identified the192 Chemistry & Biology 20, 188–201, February 21, 2013 ª2013 Elsefollowing eicosanoids: prostaglandin (PG)D2, PGE2, and throm-
boxane (Tx)B2 from the cyclooxygenase pathways and LTB4
from the 5-lipoxygenase (LOX) pathway (Figure 5A). Identifica-
tions were validated using published criteria (Dalli and Serhan,
2012), as illustrated for TxB2 and PGE2 (Figure 5B). Using
multiple reaction monitoring (MRM), we quantified individual
mediator levels and found that systemically delivered RvD3
significantly reduced LTB4 (80%), PGD2 (67%), and TxB2
(50%), while stimulating the production of PGE2 (Figure 5C).
AT-RvD3 reduced local LTB4, PGD2, and TxB2 levels, while
increasing PGE2 (Figure 5D). Together, these results demon-
strate that both synthetic RvD3 and AT-RvD3 possess potent
anti-inflammatory actions, regulating local eicosanoid levels,
characteristic of specialized proresolving mediators.
RvD3 and AT-RvD3 Exert Potent Proresolving Actions
Having found that both RvD3 and AT-RvD3 exert potent anti-
inflammatory and proresolving actions in murine systems in vivo,
we next investigated their actions with human leukocytes.
Exposure of human PMN to RvD3 or AT-RvD3 at concentrations
as low at 1011 M reduced transmigration 25% (Figure 6A).
AT-RvD3 displayed greater antimigratory properties at 1 and
10 pM (p < 0.05). We next assessed the ability of both RvD3
and its aspirin-triggered form to stimulate macrophage phago-
cytosis, a key step in the resolution of inflammation (Serhan
and Savill, 2005). Incubation of murine naive peritoneal macro-
phages with RvD3 or AT-RvD3 dose-dependently increased
macrophage phagocytosis of zymosan particles (Figure 6B). At
10 and 100 pM, AT-RvD3wasmore potent than RvD3. Together,
these results demonstrate that both RvD3 epimers exert potent
anti-inflammatory and proresolving actions with leukocytes.
Since removal of apoptotic cells and cellular debris, a process
termed efferocytosis, is a cellular hallmark of tissue resolution
(Serhan and Savill, 2005), we next assessed whether RvD3 and
its aspirin-triggered epimer stimulated murine macrophage
efferocytosis, a cardinal proresolving action essential for com-
plete resolution. Synthetic RvD3 and AT-RvD3 were each found
to potently stimulate macrophage efferocytosis of apoptotic
human PMN (Figures 6C and S4A). Next, we determined the
rank order potencies of specialized proresolving mediators
(SPM) and found that RvD3 and PD1 at 1 nM were the most
potent in stimulating efferocytosis with both mouse bone
marrow and resident macrophages, followed by MaR1, RvD2,
and RvD1 (Figures 6D and S4B). These results demonstrate
and confirm the potent anti-inflammatory and proresolving
actions defining RvD3 and AT-RvD3 with synthetic materials
and human and mouse leukocytes, as well as reducing levels
of proinflammatory cytokines, i.e., MCP-1, IL-6, and KC
(Figure 4).
Activation of Human GPR32
We next tested whether RvD3 activates the human RvD1
receptor (DRV1) GPR32, since we identified a specific G
protein-coupled receptor (GPCR), denoted GPR32, that is acti-
vated by RvD1 (Krishnamoorthy et al., 2010, 2012) and RvD5
(Chiang et al., 2012). We employed electrical cell substrate
impedance sensing (ECIS), which monitors impedance changes
upon ligand binding to receptors (Krishnamoorthy et al., 2012). In
this system, RvD3 (25.8 ± 5.0 U) and AT-RvD3 (20.7 ± 3.6 U)vier Ltd All rights reserved
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Figure 4. RvD3 Is a Potent Antineutrophil and Cytokine Regulator
RvD3, AT-RvD3 (10 ng/mouse), or vehicle (saline containing 0.1% EtOH) was administered i.v. 10 min prior to i.p. injection of zymosan (1 mg/mouse). Exudates
were collected 4 hr later.
(A) Cells were enumerated and PMN identified using flow cytometry.
(B and C) IL-6 (B) and IL-10 (C) levels were measured in peritoneal exudates. Results are mean ± SEM, n = 4 mice per group. *p < 0.05 and ***p < 0.001 versus
zymosan plus vehicle.
Dorsal skin inflammation (see Experimental Procedures): mice were injected on day six with murine recombinant TNF-a (100 ng/mouse) following administration
of RvD3, AT-RvD3 (10 ng), or vehicle (saline containing 0.1% EtOH) by intrapouch injection and at 4 hr lavages obtained.
(D) PMN by flow cytometry.
(E–G) Levels of (E) MCP-1, (F) IL-6, and (G) KC. Results are mean ± SEM, n = 4 mice per group. *p < 0.05; **p < 0.01 versus TNF-a plus vehicle.
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Figure 5. RvD3 and AT-RvD3 Reduce Local Prostanoids and Leukotrienes in Acute Inflammation
Lipid mediators in peritoneal exudates collected 4 hr after zymosan administration were assessed using LC-MS-MS metabololipidomics following solid phase
extraction.
(A) Representativemultiple reactionmonitoring chromatograms (MRM) of selected ion pairs for arachidonic acid-derived eicosanoids. a= 6-trans-LTB4 and b= 6-
trans, 12-epi-LTB4.
(B) Representative MS-MS spectra with diagnostic ions employed for the identification of TxB2 and PGE2 (see Experimental Procedures).
(C and D) Quantification of exudate lipid mediators following (C) RvD3 and (D) AT-RvD3 administration. Results are mean ± SEM, n = 4mice per group. *p < 0.05,
**p < 0.01 versus zymosan plus vehicle.
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Figure 6. RvD3 and AT-RvD3 Proresolving
Actions
(A) Human neutrophils were labeled with CFDA
and incubated with RvD3, AT-RvD3, or vehicle
(DPBS containing 0.1% EtOH) for 15 min (37C)
prior to assessing their transmigration across
human umbilical vein endothelial cells exposed
to TNF-a (10 ng/ml). Results are representative of
n = 4 distinct PMN preparations.
(B–D) Increased macrophage phagocytosis and
efferocytosis. Murine peritoneal resident macro-
phages were incubated with (B andC) RvD3 (black
square), AT-RvD3 (open circle) (0.1 pM–10 nM) or
(D) 1 nM of select SPM (15 min, 37C) followed
by addition of (B) FITC-zymosan or (C and D)
CFDA-labeled apoptotic PMN for 1 hr (see also
Figure S4). Results are mean ± SEM of n = 4, d =
3–4. *p < 0.05, **p < 0.01, ***p < 0.001 versus
vehicle; # p < 0.05, RvD3 versus AT-RvD3; + p <
0.05 versus RvD1.
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Chinese hamster ovary (CHO) cells expressing recombinant
human GPR32 (Figure 7A), to a similar magnitude as RvD1
(19.1 ± 1.8 U) (Krishnamoorthy et al., 2012). These changes
in impedancewere reducedwhen cells were incubated with anti-
human GPR32 antibody (30 min, 37C) prior to the addition of
RvD1, RvD3, or AT-RvD3 (Figures 7B–7D).
To further examine ligand-receptor relationships, we used
a beta-arrestin reporter system (Krishnamoorthy et al., 2012),
which confirmed that both RvD3 and AT-RvD3 directly activated
this receptor (0.1 pM–10 nM; Figure S5A). In addition, phagocytic
activity with human macrophages increased by RvD3 and
AT-RvD3 proved to be dependent on GPR32, since phagocy-
tosis was significantly enhanced with GPR32 overexpression
compared to mock transfected cells (Figures 7E, 7F, S5B, and
S5C). Together, these results demonstrated that RvD3 and
AT-RvD3 each activated human GPR32, which contributes to
their proresolving actions in stimulating macrophage uptake of
microbial particles (Figures 7E and 7F).
DISCUSSION
Mounting evidence indicates that resolution of acute inflamma-
tion is an active process, where lipid mediators play a pivotal
role (Serhan, 2011). In this regard, the resolvins have emerged
as uniquely positioned within the resolution phase of acute
inflammation to actively counterregulate the initiation signals
as well as stimulate specific proresolving responses. Initiation
of an inflammatory response involves the orchestrated traf-Chemistry & Biology 20, 188–201, February 21, 2013ficking of leukocytes from peripheral
blood into the tissue. The chemical
mediators involved are lipid mediators,
such as the eicosanoids, prostaglandins,
and leukotrienes (Samuelsson, 2012;
Shimizu, 2009) and the proinflammatory
cytokines and chemokines (Dinarello,
2010). The stereoselective actions are
a hallmark of the lipid-derived mediators,since they evoke potent and cell type-specific actions (Coulthard
et al., 2012; Samuelsson, 2012). Hence, given the potent actions
of the D-series resolvins, including resolvins D1 and D2, it was
deemed important to establish the when and where, i.e.,
temporal relationships and actions of resolvin (Rv) D3, within
inflammation resolution.
In the present report, we establish the complete stereochem-
istry of RvD3 and its aspirin-triggered 17R epimer, AT-RvD3.
Within the time course of self-limited local inflammatory
response, RvD3 stood apart from the other D-series resolvins in
that it remained elevated well into the late resolution phase. The
complete stereochemistry ofRvD3derived frommouseexudates
as well as human leukocytes wasmatched to synthetic materials
defined by stereocontrolled organic synthesis and NMR. The
complete structure of RvD3 proved to be 4S,11R,17S-trihydrox-
ydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid and its aspirin-
triggered epimer 4S,11R,17R-trihydroxydocosa-5Z,7E,9E,13-
Z,15E,19Z-hexaenoic acid (Figures 1, 2, and 3). Both RvD3
and its aspirin-triggered epimer potently counterregulate
proinflammatory mediators as well as limit neutrophil infiltration
in vivo. Translating to human cells, both RvD3 and AT-RvD3
blocked human neutrophil transmigration across endothelial
cells (Figure 6), a response pivotal to regulating the size of the
inflammatory exudate in situ and potential collateral tissue
damage (Majno et al., 1982). Importantly, RvD3 proved to be
a potent enhancer of the uptake of apoptotic neutrophils by
macrophages as well as a stimulator of IL-10. Together, these
results establish the structural assignments and the elucidation
of the isolated bioactive RvD3 and AT-RvD3 (Serhan et al., 2002).ª2013 Elsevier Ltd All rights reserved 195
A B
C D
E F
Figure 7. RvD3 and AT-RvD3 Activate
Human GPR32
(A–D) Ligand–receptor-dependent changes in
impedance with CHO cells overexpressing human
GPR32. Impedance was continuously recorded
with real-time monitoring across cell monolayers
using an ECIS system. Results are tracings
obtained from incubations of RvD1, RvD3, or
AT-RvD3 (100 nM each) with CHO-GPR32 cells (A)
or in the presence of anti-GPR32Abor nonimmune
rabbit serum IgG (B–D). Results are expressed as
(A) means from four separate tracings with each
compound or (B–D) representative of three sepa-
rate experiments. IgG, immunoglobulin G.
(E and F) Human GPR32 or mock-transfected
human macrophages were incubated with RvD3
or AT-RvD3 (0.1 pM–10 nM) for 15 min, followed
by addition of FITC-zymosan (60 min, 37C).
Results are expressed as mean ± SEM; n = 4
macrophage preparations. *p < 0.05, macro-
phages (MF) plus GPR32 versus MF plus mock
(see also Figure S5).
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a proresolving mediator and immunoresolvent (Serhan, 2007,
2011). Resolvin D3 fulfilled these defining criteria as well as
proved to be among the most potent of the resolvins identified
to date within inflammatory exudates. It is now widely acknowl-
edged that proinflammatory mediators, when produced in
excess, can disrupt normal resolution that can lead to chronic
inflammation (Serhan andSavill, 2005) and even to an eicosanoid
storm via rapid activation of the inflammasome (von Moltke
et al., 2012). Active containment via enhanced phagocytosis of
microbes as well as the efferocytosis of apoptotic PMN leads
to the clearance of invaders and cellular debris to return to
homeostasis (Chiang et al., 2012). Having established the pro-
resolving bioaction, complete stereochemistry, and synthesis
of RvE1, RvD1, and RvD2 as well as PD1 (reviewed in Serhan
and Petasis, 2011) permitted demonstration of their potent
actions by others in many diverse systems, including colitis
(Bento et al., 2011) and controlling pain (Ji et al., 2011), as well
as regulating important processes, such as macrophage polari-
zation and promoting resolution of adipose tissue inflammation
in obesity (Titos et al., 2011).
Resolvin D3 is distinguished from resolvins D1 and D2 by its
late appearance in vivo, promoting proresolving actions with
human leukocytes as well as in vivo (Figures 4, 5, 6, 7, and 8).196 Chemistry & Biology 20, 188–201, February 21, 2013 ª2013 Elsevier Ltd All rights reservGiven the strategic ‘‘late appearance’’ of
RvD3 during resolution of inflammation
(Figure 1), it is very likely that RvD3 is
produced by macrophage subtypes
known to appear late within the resolution
phase of self-limited response to chal-
lenge (Stables et al., 2011). Figure 8
depicts the DHA resolution metabolome
and the position of RvD3 within the
resolvin biosynthesis pathway and its
relation to other families of DHA-derived
bioactive mediators, i.e., protectins,
maresins, and resolvin family members.These late resolution-phase macrophages display high levels
of 15-LOX and, hence, the capacity to produce proresolving
mediators (Dalli and Serhan, 2012; Stables et al., 2011).
Using metabolomic approaches, as in the present study
(Figure 1), has led to identification of previously unexplored
biochemical pathways in inflammation and its resolution as
well as in many other disease processes (Levy et al., 2001; Patti
et al., 2012; Serhan et al., 2000). We have used this approach
to profile the mediators and cell types within the initiation and
resolution response (Figure 1), demonstrating that there is
a clear temporal dissociation between the initiation and reso-
lution phase of self-limited acute inflammatory response, self-
limited in that it resolves on its own. We also devised quantitative
indices in order to evaluate substances that regulate the magni-
tude and duration of the inflammatory response and its subse-
quent resolution (Bannenberg et al., 2005). Thus, if an acute
inflammatory response does not resolve, the potential for it to
progress to chronic inflammation and/or abscess formation
may lie in the extent of the presence of proinflammatory media-
tors or, consequently, the potential loss and/or delay in the
accumulation of proresolving mediators.
In murine peritonitis, the production of both PGE2 and LTB4
anteceded the production of D-series resolvins. Importantly,
PGD2 and PGE2 levels linger during the time course of resolutioned
Figure 8. DHA Resolution Metabolome
Biosynthetic scheme for D-series resolvins and their relation to protectins and maresins. The position of RvD3 is depicted and that of the aspirin-triggered RvD3
within the D-series resolvins. Note that the complete stereochemistry of RvD1, RvD2, and RvD3 are established as shown. See text for further details.
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Resolvin D3 Is a Potent Immunoresolvent(Figure 1B), and as demonstrated earlier, PGE2 and PGD2 in iso-
lated human leukocytes activate the translation of messenger
RNA to 15-LOX type I, a pivotal enzyme in production of lipoxins
(reviewed in Romano, 2010) as well as D-series resolvins
(Figure 1C). The finding that RvD3 persists well into the resolu-
tion phase and the return to homeostasis suggests that, in
addition to counterregulating proinflammatory-initiating chemi-
cal mediators, such as the prostaglandins and cytokines, and
regulating leukocyte traffic and functions, as demonstrated
herein, RvD3 can also play a role in other metabolic processes
relevant to homeostasis.
Resolvins regulate target cell expression of proinflammatory
cytokines at transcriptional as well as at translational levels
by interacting with specific receptors on the surface of leuko-
cytes (Chiang et al., 2012). Proresolving mediators, including
resolvins, also regulate adhesion molecules (i.e., CD11b/CD18)
on leukocytes that downregulate cell-cell interactions (Dona
et al., 2008; El Kebir et al., 2012). Although not formally
addressed here in the context of RvD3, the reduction in proin-Chemistry & Biology 20, 188flammatory cytokines and eicosanoids (i.e., LT) by this mediator
along with its aspirin-triggered form are likely to also reflect the
regulation of cell-cell interactions, as is the case with lipoxins,
which reduce cell adhesion molecules, cell-cell interactions,
and transcellular biosynthesis of lipid mediators (LM) (Brady
and Serhan, 1992).
Aspirin, in addition to having an antithrombotic role and
ability to block platelet thromboxane production (Samuelsson,
2012), was the lead agent used to produce nonsteroidal
anti-inflammatories that could also block prostaglandin pro-
duction (Vane, 1982). The well-appreciated antithrombotic
properties of aspirin were revealed via the structural elucidation
of thromboxane A2 (Samuelsson, 1982). However, the anti-
inflammatory actions of low-dose aspirin (75–81 mg doses)
and its anti-inflammatory capacity with antineutrophil activities
were not appreciated until the aspirin-triggered pathways for
novel anti-inflammatory mediators were uncovered (Chiang
and Serhan, 2004; Morris et al., 2009). It is now apparent
from evidence obtained by many investigators (for example,–201, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 197
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Resolvin D3 Is a Potent ImmunoresolventCla`ria and Planaguma`, 2005 and references within Maderna and
Godson, 2005 and Wu et al., 2012) that aspirin can jump-start
resolution by not only blocking thromboxane and certain prosta-
glandins, but also by triggering aspirin-triggered lipid mediators,
such as the aspirin-triggered lipoxins and the aspirin-triggered
resolvins (Serhan et al., 2002).
Along these lines, aspirin-triggered lipoxin A4 (LXA4) is
produced on dermal challenge (Morris et al., 2009), and a stable
aspirin-triggered LXA4 analog 15R/S-methyl-LXA4 was found
effective in treating infantile eczema in a double-blind two-center
clinical trial (Wu et al., 2012). Hence, the complete structural
elucidation of the aspirin-triggered lipid mediators (Chiang and
Serhan, 2004; Serhan et al., 2002) can have far-reaching implica-
tions for clinical utility. In the present experiments, the aspirin-
triggered 17R form of resolvin D3 proved to be highly potent
(Figures 4, 5, 6, and 7), as is the case for other aspirin-triggered
lipid mediators. The acetylation of cyclooxygenase-2 (COX-2) by
aspirin imposes restrictions in size in the catalytic pocket, which
blocks prostaglandin production, but still leads to the oxidation
of polyunsaturated fats, such as arachidonic acid and DHA in
vascular endothelial cells and mucosal epithelial cells. In the
case of DHA, 17R-hydroxy-docosahexaenoic acid (17-HDHA)
is produced. Albeit at low enzyme catalytic turnover levels, the
17R-HDHA precursor is produced by endothelial cells (Serhan
et al., 2000, 2002) that have an extensive biomass in humans,
in that the endothelium lines vessels from head to toe in all
organs, making this a relevant site to produce 17R-HDHA in vivo
(Serhan et al., 2002), as is the case for COX-2 in mucosal
epithelia that also has an extensive biomass and surface area
lining the barrier function of many organs (Louis et al., 2005;
Serhan et al., 2002).
In the clinical scenario in the USA, aspirin is commonly admin-
istered at one of three doses, 81, 325, or 650 mg daily (Chiang
et al., 2004; Furst and Hillson, 2001). The lower dose of 81 mg
daily is the antithrombotic dose and gives both reduction in
peripheral blood TXB2 levels and a concomitant increase in
AT-15-epi-LXA4 in healthy volunteers (Chiang et al., 2004).
Biosynthesis of AT-15-epi-LXA4 following low-dose aspirin
administration is activated on dermal challenge in human sub-
jects and regulates neutrophil influx, demonstrating the anti-
inflammatory actions of low-dose aspirin (Morris et al., 2009).
This protective action of low-dose aspirin is a function of both
age and gender, in that men older than 50 display reduced
capacity to produce AT-lipid mediators (Chiang et al., 2006;
Morris et al., 2010). Since RvD3 appears late in the resolution
phase in murine exudates (Figure 1), the biosynthesis of its
aspirin-triggered epimer would also be expected to occur late
into the resolution phase at the site of inflammation within
tissues. This, along with the findings that the aspirin-triggered
epimer 17R-resolvin D1 is characteristically more resistant to
enzymatic inactivation (Sun et al., 2007), likely leads to elevated
local levels of RvD3 and AT-RvD3. Hence, AT-RvD3 may also
provide an attractive biomarker of aspirin therapy in humans.
Studies addressing structure activity relationships of prore-
solving mediators demonstrate that R and S chirality at carbons
7 and 8 from the carboxylic acid end of DHA, i.e., RvD1, and
carbons 5 and 6 in arachidonic acid, i.e., LXA4, are critical in
dictating the ability of these resolvins and lipoxins to engage
their respective receptors (Serhan and Petasis, 2011), for198 Chemistry & Biology 20, 188–201, February 21, 2013 ª2013 Elseexample, 7S,8R in RvD1. These receptors appear to be more
flexible with respect to the chirality of the hydroxyl group at
carbon 17 for the resolvins and carbon 15 for the lipoxins,
whereby mediators with either R or S stereochemistry at these
positions are able to bind and activate their cognate GPCR to
a similar extent (Chiang et al., 2000; Krishnamoorthy et al.,
2012). This is also the case for RvD3 and its aspirin-triggered
form, which we find here to bind and activate DRV1/GPR32 to
a similar extent to each other as well as RvD1 (Figure 7).
It is noteworthy that 17-HDHA is present in the blood of healthy
individuals (Mas et al., 2012; Psychogios et al., 2011) and is
bioactive in animal disease models (Bento et al., 2011; Lima-
Garcia et al., 2011), likely as a result of its local transformation
by leukocytes to D-series resolvins (Serhan et al., 2002). In
addition, the 17R aspirin-triggered lipid mediators, such as
aspirin-triggered RvD1, remain elevated in tissues longer
because they are less susceptible to local inactivation via
dehydrogenation (Serhan, 2007). In this regard, aspirin-triggered
RvD3 also proved to be a potent mediator in blocking neutrophil
transmigration as well as enhancing proresolving responses
(Figure 6), such as other aspirin-triggered members of the DHA
metabolome (Serhan and Petasis, 2011). Regulating neutrophil
responses can prevent collateral tissue damage and, unlike
other agents that are anti-inflammatory, the resolvins and partic-
ularly D-series resolvins do this without immune suppression, as
D-series resolvins, i.e., resolvin D2 and resolvin D5, enhance
bacterial clearance in sepsis (Spite et al., 2009) and infections
(Chiang et al., 2012).
Recently, lymph nodes were found to produce 17-HDHA,
where it enhances antibody production, and the D-series resol-
vins and metabolome are also present in other lymphoid tissues
of the mouse, such as spleen (Ramon et al., 2012). Hence, it is
likely that, in addition, to the role of specialized proresolving
mediators in bringing acute inflammation to homeostasis, pre-
venting a potential for chronicity, these mediators may also
play a role in acquired immunity. Although the levels in mice
of n-3 essential fatty acids (e.g., EPA and DHA) and n-6 (e.g.,
arachidonic acid) (Weldon and Whelan, 2011) are different from
those in human tissues (De Caterina, 2011), there is still a prevail-
ing notion that n-3 fatty acids, such as DHA, have important
actions in maintaining human health and preventing disease
(Calder, 2012), including cardiovascular diseases (De Caterina,
2011). With the complete stereochemistry of RvD3 assigned
in the present studies, namely its double-bond geometry,
chirality of its alcohols, as well as anti-inflammatory and prore-
solving actions, they now permit gauging RvD30s role in the
DHA metabolome of bioactive molecules.
SIGNIFICANCE
The results of the present report establish the stereochem-
istry of RvD3 and its aspirin-triggered form produced by
human macrophages and in murine inflammatory exudates
during inflammation resolution. These results also place
the endogenous accumulation of RvD3 within the late
phase of the acute inflammatory response. RvD3 and its
aspirin-triggered form both displayed potent anti-inflamma-
tory (i.e., regulating polymorphonuclear leukocyte tissue
infiltration and proinflammatory mediator production) andvier Ltd All rights reserved
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Resolvin D3 Is a Potent Immunoresolventproresolving actions (i.e., stimulating macrophage efferocy-
tosis and phagocytosis). The present findings provide
opportunities to evaluate the role of the docosahexaenoic
acid resolution metabolome (Serhan, 2007) that can also
be evoked with aspirin treatment. Thesemediators facilitate
the transition from acute inflammation to homeostasis
without immunosuppression.
EXPERIMENTAL PROCEDURES
NMR of Synthetic RvD3
The following chemical shifts and coupling constants were recorded (for more
details, see Figure 2): H5 (5.42 ppm), H6 (6.08 ppm, J = 4.4, 11.2 Hz), H7
(6.59 ppm, J = 11.4, 14.7 Hz), H8 (6.24 ppm, J = 10.7, 14.7 Hz), H9 (6.33
ppm, J = 10.7, 15.1 Hz), H10 (5.75 ppm, J = 15.1, 6.6 Hz), H13 (5.47 ppm),
H14 (6.08 ppm, J = 4.4, 11.2 Hz), H15 (6.52 ppm, J = 11.1, 15.3 Hz), H16
(5.70 ppm, J = 6.5, 15.1 Hz), H19 (5.44 ppm), and H20 (5.37 ppm).
Acute Inflammation
Male FVB mice (6 to 8 weeks old) purchased from Charles River Laboratories
were fed ad libitum Laboratory Rodent Diet 20-5058 (Lab Diet, Purina Mills). All
animal experimental procedures were approved by the Standing Committee
on Animals of Harvard Medical School (protocol no. 02570) and complied
with institutional and US National Institutes of Health (NIH) guidelines. Perito-
nitis: Zymosan (1 mg/ml; Sigma-Aldrich) was injected intraperitoneally (i.p.)
10 min after intravenous (i.v.) administration of RvD3, AT-RvD3 (10 ng), or
vehicle (0.1% EtOH in 100 ml saline). Peritoneal lavages were collected 4–
72 hr after zymosan administration. Leukocyte numbers and differential
counts were assessed using Turks solution and flow cytometry analysis as
detailed below. Cytokine and chemokine levels were assessed in cell-free
supernatants by multiplex ELISA. Lavages were also placed in two volumes
of methanol and subjected to lipid mediator metabololipidomics. Dorsal skin
pouch: 2.5 ml of sterile air were injected subcutaneously on days 0 and 3.
On day 6, mouse recombinant TNF-a (100 ng/mouse; R&D Systems) was
administered into the airpouch in combination with either RvD3 or AT-RvD3
(10 ng/mouse). Four hours later, pouches were lavaged with Dulbecco’s
phosphate-buffered saline (DPBS)/, leukocytes were enumerated, and
a differential count was conducted; cytokine/chemokine and lipid mediator
levels were assessed as above.
Flow Cytometry
Murine peritoneal and airpouch exudate cells were suspended in fluores-
cence-activated cell sorting (FACS) buffer (5% BSA in DPBS) and incubated
with Fc block (15 min, 4C; BD PharMingen) and then rat antimouse (from
eBioscience) CD11b-PerCP/Cy5.5 (Clone:M1/70) and Ly6G- fluorescein iso-
thiocyanate (FITC) (Clone 1A8) (30 min, 4C) or appropriate isotype controls.
Staining was assessed using FACSDiva CantoII (BD Biosciences) and
analyzed using FlowJo (Tree Star).
Leukocyte Functional Responses
Macrophage Phagocytosis and Efferocytosis
To obtain apoptotic PMN, human PMN were isolated by density-gradient
Ficoll-Histopaque from human peripheral blood. Blood was obtained from
healthy human volunteers giving informed consent under protocol # 1999-P-
001297 approved by the Partners Human Research Committee. PMN were
labeled with carboxyfluorescein diacetate-succinimidyl ester (CFDA; 10 mM,
30 min, 37C) and cultured overnight (5 3 106 cells/ml in DPBS+/+). Mouse
resident peritoneal macrophages (MF) were plated onto 96-well plates
(Costar) at 53 104 cells/well and incubated with SPM (15 min, 37C) followed
by phagocytosis of fluorescent-labeled apoptotic PMN or FITC zymosan, as
described (Dalli and Serhan, 2012). Fluorescent-labeled PMN were then
added at a 3:1 ratio (PMN to macrophages).
Human macrophages were prepared from peripheral blood mononuclear
cells (Dalli and Serhan, 2012). Macrophages (3 3 106 cells in a 10 cm petri
dish) were transfected with pcDNA3 or with expression vector for human
GPR32 (5 mg) using Jet-Pei transfection reagent following the manufacturer’s
instructions (Polyplus-transfection SA). After transfection (48 hr), cells wereChemistry & Biology 20, 188plated onto 96-well plates (50,000 cells/well), and phagocytosis was carried
out 24 hr after replating. Expression of GPR32 was verified by flow cytometry
using a polyclonal rabbit antihuman GPR32 antibody (GeneTex, GTX108119).
Phagocytosis was then assessed vide supra. PMN transendothelial migration
was performed as in Serhan et al. (2002).
Lipid Mediator Metabololipidomics
All samples for LC-MS-MS-based lipidomics were subject to solid-phase
extraction as in Dalli and Serhan (2012). Prior to sample extraction, d4-LTB4
and d4-PGE2, representing each region in the chromatographic analysis
(500 pg each), were added to facilitate quantification. Extracted samples
were analyzed by a liquid chromatography-ultraviolet-tandem mass spec-
trometry system, QTrap 5500 (ABSciex) equipped with an Agilent HP1100
binary pump and diode-array detector. An Agilent Eclipse Plus C18 column
(50 mm 3 4.6 mm 3 1.8 mm) was used with a gradient of methanol/water/
acetic acid of 55:45:0.01 (v/v/v) to 100:0:0.01 at 0.5 ml/min flow rate. To
monitor and quantify the levels of targeted LMs, we used multiple reaction
monitoring (MRM) with signature ion fragments for each molecule (six diag-
nostic ions and calibration curves) (Dalli and Serhan, 2012). GC-MS was
carried out as in Serhan et al. (2002).
GPCR-Beta-Arrestin System and Ligand-Receptor Interactions
Ligand-receptor interactions were monitored using the Beta Arrestin Path-
Hunter system (Discoverx) and carried out essentially as in Krishnamoorthy
et al. (2012), with CHO cells stably overexpressing recombinant human
GPR32 (hGPR32: DRV1) receptors tagged with a prolink label of beta-galacto-
sidase and beta-arrestin linked to the enzyme acceptor fragment of beta-
galactosidase. Briefly, cells were plated in 96-well plates (20,000 cells/well)
24 hr prior to initiating experiments. Test compoundswere incubated with cells
(60 min, 37C), and receptor activation was determined by measuring chemi-
luminescence using the PathHunter detection kit (Discoverx).
Ligand Selectivity Using ECIS
Ligand-receptor interactions weremonitored bymeasuring impedance across
cultured CHO-hGPR32 cell monolayers using an ECIS (Applied Biophysics)
and carried out as in Krishnamoorthy et al. (2012). For antibody incubations,
anti-GPR32 antibody (Ab) or rabbit serum was incubated with cells in the
ECIS chambers at 1:50 dilutions for 30 min before addition of compounds.
Statistics
All data were expressed as means ± SEM. Differences between groups were
compared using Student’s t test (two groups) or one-way ANOVA (multiple
groups) followed by a post hoc Bonferroni test. The criterion for statistical
significance was p < 0.05.
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